What is leptospirosis and how can it harm us and our pets?

Frontier IP chief executive officer Neil Crabb said: “TVG’s novel vaccine technology has the potential to play a material role in beating the threats of antimicrobial resistance and, more widely, from life-threatening diseases which infect animals

Following a recent story with the top twenty companies in the area of AI drug development, this time we will make a flight over this new ecosystem looking for the bright lights of a rigorous developing

MSPs debated the importance of life sciences to the Scottish economy on Wednesday to mark the second anniversary of the industry-led Life Sciences Strategy. North East Scotland Conservative MSP Bill Bowman praised efforts to strengthen partnerships

Frontier IP chief executive officer Neil Crabb said: “Today’s announcements confirm Exscientia’s exciting potential. The strong support for the financing round from major companies in the life sciences industry and the collaboration with Roche strengthen our

Former AIM writer of the year Andrew Hore names the AIM companies he believes have strong growth prospects over the next year and beyond. Frontier IP (FIPP) Frontier IP (LON:FIPP) develops businesses and technologies that are

Frontier IP Group chief executive officer Neil Crabb said: “We’re delighted with the rapid progress the agreement with Palintest is making. It has taken less than 18 months from when Molendotech was first incorporated to the

Technology is constantly impacting and changing the way the world works. Greater technological innovations are not only changing the way business operates, but also have a significant impact on employees. Over the course of the next

A recent article about AI-based drug development, indicates the progressive use of A.I. technologies for the drug production industry, mining the huge amount of data collected from the pharmaceutical companies’ data centres. Thanks to Deep Knowledge

In 2013, US start-up Berg was asked by the Department of Defence to help improve the detection of prostate cancer, a disease which is common among pilots. Less than five years later, an artificial intelligence-driven tool

Frontier IP Chief Executive Officer Neil Crabb said: “We are delighted with this news from Exscientia. The acquisition adds to the exciting potential of what the Company can achieve in the field of AI-driven drug discovery.”

Neil Crabb, CEO of Frontier IP Group plc, commented: “Frontier IP is going from strength to strength. There is strong evidence that our distinctive approach to intellectual property commercialisation, designed to address the needs of both

Oxford is a hotbed of AI, deep tech, space and medtech talent, capitalising on the university city’s prowess and heritage in research and science. Home to the oldest university in the English-speaking world, the University of

The examples of AI and its applications in healthcare potentially offer affordable healthcare, efficient clinical trials, improved success rates and a better quality of life. While many of us may be familiar with AI in the

In a key point in its growth strategy, Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is expanding its Oxford presence to the new Schrödinger Building on The Oxford Science Park,

Frontier IP chief executive Neil Crabb said: “We’re very excited about the possibilities for Des Solutio. The technology being developed by Professor Ana Rita Duarte and Dr Alexandre Paiva has already attracted interest from major multinationals.

The post-lay trenching works are planned to commence late 2018 with the T1 trencher. This contract award has come on the back of three successfully completed projects with this trencher offshore UAE in 2016, early 2017

Frontier IP chief executive officer Neil Crabb said: “We’re delighted with this further industry backing for Molendotech’s unique IP. Fresh produce is one of the many sectors where we believe the Company can make a real